Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction

Norman C. Wang, Aldo P. Maggioni, Marvin A. Konstam, Faiez Zannad, Holly B. Krasa, John C Jr. Burnett, Liliana Grinfeld, Karl Swedberg, James E. Udelson, Thomas Cook, Brian Traver, Christopher Zimmer, Cesare Orlandi, Mihai Gheorghiade

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Context: Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied. Objective: To investigate the predictive value of the QRS duration in patients hospitalized for heart failure with reduced left ventricular ejection fraction (LVEF). Design, Setting, and Participants: Retrospective, post hoc analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for heart failure and having an LVEF of 40% or less. A total of 4133 patients were enrolled at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006. After excluding 1029 patients with a pacemaker, implantable cardioverter-defibrillator, or both at enrollment and 142 patients without a reported baseline QRS duration, 2962 patients were included in the analysis: 1641 had a normal QRS duration (<120 ms) and 1321 had a prolonged QRS duration (≥120 ms). Main Outcome Measures: Dual primary end points were all-cause mortality and the composite of cardiovascular death or hospitalization for heart failure. Results: During a median follow-up of 9.9 months, all-cause mortality was 18.7% for patients with a normal baseline QRS duration and 28.1% for patients with a prolonged baseline QRS duration (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.38-1.87). The composite of cardiovascular death or hospitalization for heart failure was 32.4% for patients with a baseline QRS duration less than 120 ms and 41.6% for patients with a baseline QRS duration of 120 ms or greater (HR, 1.40; 95% CI, 1.24-1.58). The increased risk associated with prolonged QRS duration was confirmed after adjusting for multiple variables for all-cause mortality (HR, 1.24; 95% CI, 1.02-1.50) and the composite of cardiovascular death or hospitalization for heart failure (HR, 1.28; 95% CI, 1.10-1.49). Only 105 patients (3.6%) who presented with a prolonged baseline QRS duration had a normal QRS duration on their last inpatient electrocardiogram. Conclusion: A prolonged QRS duration appears common in patients with reduced LVEF who are hospitalized for heart failure and is an independent predictor of high postdischarge morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)2656-2666
Number of pages11
JournalJAMA - Journal of the American Medical Association
Volume299
Issue number22
DOIs
StatePublished - Jun 11 2008

Fingerprint

Stroke Volume
Heart Failure
Hospitalization
Mortality
Confidence Intervals
Outcome Assessment (Health Care)
Morbidity
Implantable Defibrillators
Vasopressins
Inpatients
Electrocardiography
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. / Wang, Norman C.; Maggioni, Aldo P.; Konstam, Marvin A.; Zannad, Faiez; Krasa, Holly B.; Burnett, John C Jr.; Grinfeld, Liliana; Swedberg, Karl; Udelson, James E.; Cook, Thomas; Traver, Brian; Zimmer, Christopher; Orlandi, Cesare; Gheorghiade, Mihai.

In: JAMA - Journal of the American Medical Association, Vol. 299, No. 22, 11.06.2008, p. 2656-2666.

Research output: Contribution to journalArticle

Wang, NC, Maggioni, AP, Konstam, MA, Zannad, F, Krasa, HB, Burnett, JCJ, Grinfeld, L, Swedberg, K, Udelson, JE, Cook, T, Traver, B, Zimmer, C, Orlandi, C & Gheorghiade, M 2008, 'Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction', JAMA - Journal of the American Medical Association, vol. 299, no. 22, pp. 2656-2666. https://doi.org/10.1001/jama.299.22.2656
Wang, Norman C. ; Maggioni, Aldo P. ; Konstam, Marvin A. ; Zannad, Faiez ; Krasa, Holly B. ; Burnett, John C Jr. ; Grinfeld, Liliana ; Swedberg, Karl ; Udelson, James E. ; Cook, Thomas ; Traver, Brian ; Zimmer, Christopher ; Orlandi, Cesare ; Gheorghiade, Mihai. / Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. In: JAMA - Journal of the American Medical Association. 2008 ; Vol. 299, No. 22. pp. 2656-2666.
@article{fe8e6210acb74d5da5ec7f508be07294,
title = "Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction",
abstract = "Context: Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied. Objective: To investigate the predictive value of the QRS duration in patients hospitalized for heart failure with reduced left ventricular ejection fraction (LVEF). Design, Setting, and Participants: Retrospective, post hoc analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for heart failure and having an LVEF of 40{\%} or less. A total of 4133 patients were enrolled at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006. After excluding 1029 patients with a pacemaker, implantable cardioverter-defibrillator, or both at enrollment and 142 patients without a reported baseline QRS duration, 2962 patients were included in the analysis: 1641 had a normal QRS duration (<120 ms) and 1321 had a prolonged QRS duration (≥120 ms). Main Outcome Measures: Dual primary end points were all-cause mortality and the composite of cardiovascular death or hospitalization for heart failure. Results: During a median follow-up of 9.9 months, all-cause mortality was 18.7{\%} for patients with a normal baseline QRS duration and 28.1{\%} for patients with a prolonged baseline QRS duration (hazard ratio [HR], 1.61; 95{\%} confidence interval [CI], 1.38-1.87). The composite of cardiovascular death or hospitalization for heart failure was 32.4{\%} for patients with a baseline QRS duration less than 120 ms and 41.6{\%} for patients with a baseline QRS duration of 120 ms or greater (HR, 1.40; 95{\%} CI, 1.24-1.58). The increased risk associated with prolonged QRS duration was confirmed after adjusting for multiple variables for all-cause mortality (HR, 1.24; 95{\%} CI, 1.02-1.50) and the composite of cardiovascular death or hospitalization for heart failure (HR, 1.28; 95{\%} CI, 1.10-1.49). Only 105 patients (3.6{\%}) who presented with a prolonged baseline QRS duration had a normal QRS duration on their last inpatient electrocardiogram. Conclusion: A prolonged QRS duration appears common in patients with reduced LVEF who are hospitalized for heart failure and is an independent predictor of high postdischarge morbidity and mortality.",
author = "Wang, {Norman C.} and Maggioni, {Aldo P.} and Konstam, {Marvin A.} and Faiez Zannad and Krasa, {Holly B.} and Burnett, {John C Jr.} and Liliana Grinfeld and Karl Swedberg and Udelson, {James E.} and Thomas Cook and Brian Traver and Christopher Zimmer and Cesare Orlandi and Mihai Gheorghiade",
year = "2008",
month = "6",
day = "11",
doi = "10.1001/jama.299.22.2656",
language = "English (US)",
volume = "299",
pages = "2656--2666",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "22",

}

TY - JOUR

T1 - Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction

AU - Wang, Norman C.

AU - Maggioni, Aldo P.

AU - Konstam, Marvin A.

AU - Zannad, Faiez

AU - Krasa, Holly B.

AU - Burnett, John C Jr.

AU - Grinfeld, Liliana

AU - Swedberg, Karl

AU - Udelson, James E.

AU - Cook, Thomas

AU - Traver, Brian

AU - Zimmer, Christopher

AU - Orlandi, Cesare

AU - Gheorghiade, Mihai

PY - 2008/6/11

Y1 - 2008/6/11

N2 - Context: Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied. Objective: To investigate the predictive value of the QRS duration in patients hospitalized for heart failure with reduced left ventricular ejection fraction (LVEF). Design, Setting, and Participants: Retrospective, post hoc analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for heart failure and having an LVEF of 40% or less. A total of 4133 patients were enrolled at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006. After excluding 1029 patients with a pacemaker, implantable cardioverter-defibrillator, or both at enrollment and 142 patients without a reported baseline QRS duration, 2962 patients were included in the analysis: 1641 had a normal QRS duration (<120 ms) and 1321 had a prolonged QRS duration (≥120 ms). Main Outcome Measures: Dual primary end points were all-cause mortality and the composite of cardiovascular death or hospitalization for heart failure. Results: During a median follow-up of 9.9 months, all-cause mortality was 18.7% for patients with a normal baseline QRS duration and 28.1% for patients with a prolonged baseline QRS duration (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.38-1.87). The composite of cardiovascular death or hospitalization for heart failure was 32.4% for patients with a baseline QRS duration less than 120 ms and 41.6% for patients with a baseline QRS duration of 120 ms or greater (HR, 1.40; 95% CI, 1.24-1.58). The increased risk associated with prolonged QRS duration was confirmed after adjusting for multiple variables for all-cause mortality (HR, 1.24; 95% CI, 1.02-1.50) and the composite of cardiovascular death or hospitalization for heart failure (HR, 1.28; 95% CI, 1.10-1.49). Only 105 patients (3.6%) who presented with a prolonged baseline QRS duration had a normal QRS duration on their last inpatient electrocardiogram. Conclusion: A prolonged QRS duration appears common in patients with reduced LVEF who are hospitalized for heart failure and is an independent predictor of high postdischarge morbidity and mortality.

AB - Context: Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied. Objective: To investigate the predictive value of the QRS duration in patients hospitalized for heart failure with reduced left ventricular ejection fraction (LVEF). Design, Setting, and Participants: Retrospective, post hoc analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for heart failure and having an LVEF of 40% or less. A total of 4133 patients were enrolled at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006. After excluding 1029 patients with a pacemaker, implantable cardioverter-defibrillator, or both at enrollment and 142 patients without a reported baseline QRS duration, 2962 patients were included in the analysis: 1641 had a normal QRS duration (<120 ms) and 1321 had a prolonged QRS duration (≥120 ms). Main Outcome Measures: Dual primary end points were all-cause mortality and the composite of cardiovascular death or hospitalization for heart failure. Results: During a median follow-up of 9.9 months, all-cause mortality was 18.7% for patients with a normal baseline QRS duration and 28.1% for patients with a prolonged baseline QRS duration (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.38-1.87). The composite of cardiovascular death or hospitalization for heart failure was 32.4% for patients with a baseline QRS duration less than 120 ms and 41.6% for patients with a baseline QRS duration of 120 ms or greater (HR, 1.40; 95% CI, 1.24-1.58). The increased risk associated with prolonged QRS duration was confirmed after adjusting for multiple variables for all-cause mortality (HR, 1.24; 95% CI, 1.02-1.50) and the composite of cardiovascular death or hospitalization for heart failure (HR, 1.28; 95% CI, 1.10-1.49). Only 105 patients (3.6%) who presented with a prolonged baseline QRS duration had a normal QRS duration on their last inpatient electrocardiogram. Conclusion: A prolonged QRS duration appears common in patients with reduced LVEF who are hospitalized for heart failure and is an independent predictor of high postdischarge morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=44949106481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949106481&partnerID=8YFLogxK

U2 - 10.1001/jama.299.22.2656

DO - 10.1001/jama.299.22.2656

M3 - Article

C2 - 18544725

AN - SCOPUS:44949106481

VL - 299

SP - 2656

EP - 2666

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 22

ER -